Skip to content
Head to head

Aquestive Therapeutics vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: AQST · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

AQST -40.5%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
AQSTTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price3.4621.77
Change today-6.61%+1.68%
1-year return-38.4%+57.5%
Market cap$434.88M$69.76B
52-week range2.93 – 6.7413.92 – 22.07
Valuation
P/E (TTM)-5.32311.00
P/E percentile, own 5-yr range45th100th
P/B-6.151.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.78-0.30
Net profit (TTM)$-98.04M$-970.94M
Revenue (TTM)$48.84M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-41.0%+6.7%
Gross margin65.3%65.8%
Operating margin-114.1%14.3%
Net margin-162.3%0.9%
Free cash flow (TTM)$-40.70M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership57.5%51.3%
Insider activity (12mo)22 buy / 26 sell19 buy / 31 sell
Short interest (% of float)23.4%0.1%
Analyst consensus100% buy (4)100% buy (1)
Analyst price target$9 (+167%)$50 (+132%)
StockVane view
StockVane Quant RatingE (9)C (90)
Company
Employees14747,029
Founded20041781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.